Company: INTS
Filing Date: 2025-04-22
Form Type: S-1
Source: 0001628280-25-018892
Chunk: 2

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-22
Form: S-1
Chunk 2
---
 AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED.

#### Up to 4,255,319 Shares of Common Stock
<div align='center'>Up to 4,255,319 Series B-1 Common Warrants to Purchase Up to 4,255,319 Shares of Common Stock

Up to 4,255,319 Series B-2 Common Warrants to Purchase Up to 4,255,319 Shares of Common Stock

Up to 4,255,319 Pre-Funded Warrants to Purchase Up to 4,255,319 Shares of Common Stock

Up to 4,255,319 Shares of Common Stock Underlying the Pre-Funded Warrants

Up to 8,510,638 Shares of Common Stock Underlying the Series B-1 Common Warrants and Series B-2 Common Warrants</div>

We are offering on a reasonable best efforts basis up to 4,255,319 shares of our common stock, par value $0.0001 (the “Common Stock”), together with warrants to purchase up to 8,510,638 shares of our Common Stock. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock (the “Series B-1 Common Warrant”) and an additional common warrant to purchase one share of Common Stock (the “Series B-2 Common Warrant”, and together with the Series B-1 Common Warrant, the “Common Warrants”). The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. The assumed public offering price for each share of Common Stock and the accompanying Common Warrants is $1.88, which was the closing price of our Common Stock on The Nasdaq Capital Market (“Nasdaq”) on April 21, 2025.

Each Common Warrant will have an assumed exercise price per share of $1.88 (equal to the assumed combined public offering price per share of Common Stock and accompanying Common Warrants) and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants (the “Warrant Stockholder Approval